CD19 is a protein on B cells from the start until they mature. It’s always there, even on cancerous B cells. This makes CD19 ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, myasthenia gravis and other conditions traced to misdirected immune response.

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...

It exhibits a favourable balance between efficacy and toxicity. This therapy is intended for patients with the CD19 marker in B cells, a protein used to diagnose cancers stemming from B cells ...

Testing for the BRAF V600E mutation or protein and for HCL-specific immunophenotypic markers (including annexin ... 104 HCL antigens such as CD19, CD20, CD22, CD79b, and CD123 represent appealing ...

Expert Rev Hematol. 2012;5(1):69-79. As the analysis of IGHV genes is both costly and time consuming, there has been a search for surrogate markers in CLL. So far, several markers have been ...

Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...

The development of CAR-T technology in recent years has been a major milestone in the fight against cancer. These sort of ...